Please use this identifier to cite or link to this item:
https://observatorio.fm.usp.br/handle/OPI/43807
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor | Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP | - |
dc.contributor.author | BETTAMPADI, Deepti | - |
dc.contributor.author | SIRAK, Bradley A. | - |
dc.contributor.author | ABRAHAMSEN, Martha E. | - |
dc.contributor.author | REICH, Richard R. | - |
dc.contributor.author | VILLA, Luisa L. | - |
dc.contributor.author | PONCE, Eduardo Lazcano | - |
dc.contributor.author | GIULIANO, Anna R. | - |
dc.date.accessioned | 2021-12-16T14:18:43Z | - |
dc.date.available | 2021-12-16T14:18:43Z | - |
dc.date.issued | 2021 | - |
dc.identifier.citation | CLINICAL INFECTIOUS DISEASES, v.73, n.9, p.E3227-E3234, 2021 | - |
dc.identifier.issn | 1058-4838 | - |
dc.identifier.uri | https://observatorio.fm.usp.br/handle/OPI/43807 | - |
dc.description.abstract | Background. Human papillomavirus (HPV)-attributable oropharyngeal cancer (HPV-OPC) incidence is increasing in many high-income countries among men. Factors associated with oral HPV persistence, the precursor of HPV-OPC, are unknown. Data from the HPV Infection in Men (HIM) Study, which followed participants >7 years, were utilized to examine rates of persistence and associated factors. Methods. Oral gargle samples from 3095 HIM study participants were HPV genotyped using the SPF 10 PCR-DEIA-LiPA 25 assay (DDL Diagnostic Laboratory). Oral HPV persistence for individual and grouped high-risk HPV types among 184 men positive for any high-risk HPV at their oral baseline visit was assessed at 6-month intervals. Factors associated with grouped high-risk HPV/HPV16 persistence were examined using logistic regression. Kaplan-Meier curves were constructed to examine median time to HPV clearance overall, and by selected risk factors. Results. Among the 7 HPV vaccine types, HPV33 had the longest median duration (7.6 months) followed by HPV16 and HPV45 (6.4 months). 10-30% of oral high-risk HPV infections persisted >= 24 months. Six months' persistence of oral high-risk HPV infections was positively associated with age and gingivitis and negatively with lifetime number of sexual partners, while 12 months' persistence was only inversely associated with lifetime number of sexual partners. Oral HPV16 persistence was positively associated with baseline HPV16 L1 antibody status. Conclusions. Eighteen percent of HPV16 infections persisted beyond 24 months, potentially conferring higher risk of HPV-OPC among these men. Older age appears to be an important factor associated with oral high-risk HPV persistence. More studies among healthy men are required to understand the progression of oral HPV infection to HPV-OPC. | eng |
dc.description.sponsorship | National Cancer Institute at the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01 CA214588, P30-CA076292] | - |
dc.description.sponsorship | National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA | - |
dc.language.iso | eng | - |
dc.publisher | OXFORD UNIV PRESS INC | eng |
dc.relation.ispartof | Clinical Infectious Diseases | - |
dc.rights | restrictedAccess | eng |
dc.subject | oral HPV | eng |
dc.subject | HPV persistence | eng |
dc.subject | oropharyngeal cancer | eng |
dc.subject | HIM study | eng |
dc.subject | oral HPV clearance | eng |
dc.subject.other | prevalence | eng |
dc.subject.other | l1 | eng |
dc.title | Factors Associated With Persistence and Clearance of High-Risk Oral Human Papillomavirus (HPV) Among Participants in the HPV Infection in Men (HIM) Study | eng |
dc.type | article | eng |
dc.rights.holder | Copyright OXFORD UNIV PRESS INC | eng |
dc.identifier.doi | 10.1093/cid/ciaa1701 | - |
dc.identifier.pmid | 33173937 | - |
dc.subject.wos | Immunology | eng |
dc.subject.wos | Infectious Diseases | eng |
dc.subject.wos | Microbiology | eng |
dc.type.category | original article | eng |
dc.type.version | publishedVersion | eng |
hcfmusp.author.external | BETTAMPADI, Deepti:H Lee Moffitt Canc Ctr & Res Inst, Dept Canc Epidemiol, Tampa, FL USA; H Lee Moffitt Canc Ctr & Res Inst, Ctr Immunizat & Infect Res Canc, Tampa, FL USA | - |
hcfmusp.author.external | SIRAK, Bradley A.:H Lee Moffitt Canc Ctr & Res Inst, Ctr Immunizat & Infect Res Canc, Tampa, FL USA | - |
hcfmusp.author.external | ABRAHAMSEN, Martha E.:H Lee Moffitt Canc Ctr & Res Inst, Ctr Immunizat & Infect Res Canc, Tampa, FL USA | - |
hcfmusp.author.external | REICH, Richard R.:H Lee Moffitt Canc Ctr & Res Inst, Biostat & Bioinformat, Tampa, FL USA | - |
hcfmusp.author.external | PONCE, Eduardo Lazcano:Natl Inst Publ Hlth, Ctr Populat Hlth Res, Cuernavaca, Morelos, Mexico | - |
hcfmusp.author.external | GIULIANO, Anna R.:H Lee Moffitt Canc Ctr & Res Inst, Dept Canc Epidemiol, Tampa, FL USA; H Lee Moffitt Canc Ctr & Res Inst, Ctr Immunizat & Infect Res Canc, Tampa, FL USA | - |
hcfmusp.description.beginpage | E3227 | - |
hcfmusp.description.endpage | E3234 | - |
hcfmusp.description.issue | 9 | - |
hcfmusp.description.volume | 73 | - |
hcfmusp.origem | WOS | - |
hcfmusp.origem.id | WOS:000753398700179 | - |
hcfmusp.origem.id | 2-s2.0-85120421321 | - |
hcfmusp.publisher.city | CARY | eng |
hcfmusp.publisher.country | USA | eng |
hcfmusp.relation.reference | Beachler DC, 2015, SEX TRANSM DIS, V42, P93, DOI 10.1097/OLQ.0000000000000236 | eng |
hcfmusp.relation.reference | Bettampadi D, 2020, PAPILLOMAVIRUS RES, V9, DOI 10.1016/j.pvr.2020.100199 | eng |
hcfmusp.relation.reference | Campbell CMP, 2016, J INFECT DIS, V214, P45, DOI 10.1093/infdis/jiw083 | eng |
hcfmusp.relation.reference | Chaturvedi AK, 2011, J CLIN ONCOL, V29, P4294, DOI 10.1200/JCO.2011.36.4596 | eng |
hcfmusp.relation.reference | D'Souza G, 2020, JNCI CANCER SPECT, V4, DOI 10.1093/jncics/pkaa047 | eng |
hcfmusp.relation.reference | Frisch M, 2000, JNCI-J NATL CANCER I, V92, P1500, DOI 10.1093/jnci/92.18.1500 | eng |
hcfmusp.relation.reference | Gillison ML, 2012, JAMA-J AM MED ASSOC, V307, P693, DOI 10.1001/jama.2012.101 | eng |
hcfmusp.relation.reference | Giuliano AR, 2008, CANCER EPIDEM BIOMAR, V17, P2036, DOI 10.1158/1055-9965.EPI-08-0151 | eng |
hcfmusp.relation.reference | Kero K, 2014, EUR J CLIN MICROBIOL, V33, P123, DOI 10.1007/s10096-013-1938-1 | eng |
hcfmusp.relation.reference | Kleter B, 1998, AM J PATHOL, V153, P1731, DOI 10.1016/S0002-9440(10)65688-X | eng |
hcfmusp.relation.reference | Kreimer AR, 2011, CANCER EPIDEM BIOMAR, V20, P172, DOI 10.1158/1055-9965.EPI-10-0682 | eng |
hcfmusp.relation.reference | Lowy DR, 2015, LANCET ONCOL, V16, pE226, DOI 10.1016/S1470-2045(15)70075-6 | eng |
hcfmusp.relation.reference | Nasman A, 2009, INT J CANCER, V125, P362, DOI 10.1002/ijc.24339 | eng |
hcfmusp.relation.reference | Campbell CMP, 2015, CANCER PREV RES, V8, P190, DOI 10.1158/1940-6207.CAPR-14-0296 | eng |
hcfmusp.relation.reference | Tezal Mine, 2012, Int J Otolaryngol, V2012, P575242, DOI 10.1155/2012/575242 | eng |
hcfmusp.relation.reference | Tezal M, 2009, ARCH OTOLARYNGOL, V135, P391, DOI 10.1001/archoto.2009.6 | eng |
dc.description.index | MEDLINE | eng |
dc.identifier.eissn | 1537-6591 | - |
hcfmusp.citation.scopus | 2 | - |
hcfmusp.scopus.lastupdate | 2022-06-09 | - |
Appears in Collections: | Artigos e Materiais de Revistas Científicas - FM/MDR Artigos e Materiais de Revistas Científicas - LIM/24 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
art_BETTAMPADI_Factors_Associated_With_Persistence_and_Clearance_of_HighRisk_2021.PDF Restricted Access | publishedVersion (English) | 1.81 MB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.